Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

By Nikita Chaurasia  | Date: 2021-03-25

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

Pfizer Inc., an American multinational pharmaceutical corporation, has recently announced to have started the early phase trials for its oral antiviral drug for Coronavirus. The company revealed that first phase trials of the experimental drug, PF-07321332, are currently being conducted in the U.S.

The new drug pertains to the protease inhibitor class of antiviral drugs and can prevent viral replication in human cells, by blocking the production of an enzyme. For those unaware, protease inhibitors are commonly used for the treatment of viral pathogens like Hepatitis C and HIV.

Chief Scientific Officer of Pfizer, Mikael Dolsten reportedly said that both modes of prevention using vaccines and treatment for those affected with the virus are equally important to manage the coronavirus pandemic. The rapid mutation of SARS-CoV-2 along with the continued impact of the ongoing pandemic has necessitated access to curative measures in the long run.

The phase one trials for the oral antiviral drug are being performed in tandem with Pfizer’s development of PF-07304814, an intravenously administered protease inhibitor. The drug is currently in a phase 1 B clinical trial and is currently being tested on patients admitted in hospitals with COVID-19.

Even though drugmakers such as BioNTech and Pfizer have had their vaccines approved in the United States, analysts opine that the world will require a variety of drugs to arrest the pandemic.

Meanwhile, preclinical studies have exhibited that the oral drug, which is the first protease inhibitor to be analyzed in clinical trials, has a strong antiviral capacity against the virus, according to the firm.

The drug may be recommended to individuals who are newly infected with the virus as it can be ingested orally. Researchers hope that the drug will slow the progression of the disease and keep people out of the hospital.

Pfizer divulged that it would provide more information on the drug’s progress on 6th April 2021 at the American Chemical Society Spring Meeting.

Source Credit –

https://www.news18.com/news/world/pfizer-starts-early-stage-clinical-trial-testing-of-oral-antiviral-drug-for-coronavirus-report-3566318.html

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

ZeroAvia buys HyPoint to strengthen hydrogen fuel-cell technology offering

ZeroAvia buys HyPoint to strengthen hydrogen fuel-cell technology offering

By Nikita Chaurasia

British/American hydrogen-electric aircraft developer, ZeroAvia has wholly purchased HyPoint, a hydrogen fuel cell system provider, to strengthen its hydrogen-electric product portfolio. As per sources, ZeroAvia is developing powertrains for hydro...

Chanel pioneers ¬sustainability-linked bonds for combating climate changes

Chanel pioneers ¬sustainability-linked bonds for combating climate changes

By Nikita Chaurasia

French luxury fashion house well-recognized for its perfumes and tweed suits, Chanel, has reportedly unveiled ­sustainability-linked bonds, or SLBs, to combat climate change two years ago when the firm was in need to borrow money. The investor...

NLP Logix Partners and Databricks team up for Lakehouse Platform

NLP Logix Partners and Databricks team up for Lakehouse Platform

By Nikita Chaurasia

NLP Logix, a well-known predictive modeling and machine learning leader, has recently announced that it has entered into a partnership with Databricks, an American enterprise software company, to drive business value by deploying data and artificial ...

Elliptic Labs inks deal with Xiaomi to offer a proximity detection solution

Elliptic Labs inks deal with Xiaomi to offer a proximity detection solution

By Nikita Chaurasia

Elliptic Labs, a global AI software company, has reportedly entered into a new agreement with Xiaomi, one of the third-largest smartphone manufacturers across the globe. With this agreement, Xiaomi will continue to leverage INNER BEAUTY, the AI Vi...

L&T Technology Services partners with Qualcomm to amplify 5G adoption

L&T Technology Services partners with Qualcomm to amplify 5G adoption

By Nikita Chaurasia

L&T Technology Services Limited has recently announced that it is teaming up with Qualcomm Technologies, Inc., the world’s leading wireless technology innovator. With the latest collaboration, the firm plans to offer end-to-end solutions...